In this work, researchers illustrated the potential of soft x-ray tomography to rapidly characterize and quantify the structural changes induced in cells infected by SARS-CoV-2, revealing profound alterations of the subcellular architecture induced by viral infection over time. Read more »
An Antibody That Broadly Neutralizes SARS-CoV-2
An antibody that appears to neutralize all known SARS-CoV-2 strains and closely related coronaviruses was discovered with the help of the ALS. The work highlights principles underlying antibody potency, breadth, and escapability that can guide the development of therapeutics against the current and potential future pandemics. Read more »
Sifting through Fragments for COVID-19 Treatments
COVID-19 vaccines are essential for preventing serious disease, but the identification of new drugs is still necessary for the treatment of patients who become sick as a result of SARS-CoV-2 infection. Here, scientists used computational docking and crystallography to screen large numbers of small molecules for potential use in drug compounds. Read more »
Scientist at Berkeley Lab Played a Hand in “Inescapable” COVID-19 Antibody Discovery
An antibody therapy that appears to neutralize all known SARS-CoV-2 strains—including newly emerged mutants that can now “escape” from previous antibody therapies—was developed with a little help from structural biologist Jay Nix. His work helped generate detailed structural maps of how antibodies bind to the spike protein, enabling the selection of promising contenders. Read more »
Assembly of the SARS-CoV-2 Replication Mechanism
Using a multimodal approach that included x-ray scattering at the ALS, researchers determined how components of the SARS-CoV-2 replication mechanism fit together. A better understanding of how this protein complex works provides insight into potential structural or functional weak spots to exploit for drug development. Read more »
Deconstructing the Infectious Machinery of the SARS-CoV-2 Virus
Scientists collaborated to model the complex protein responsible for SARS-CoV-2 replication, revealing its potential weak spots for drug development. The investigation hinged on data collected from many advanced imaging techniques, including small-angle x-ray scattering (SAXS), crystallography, and small-angle neutron scattering (SANS). Read more »
Researchers Set Sights on Another COVID-19 Target
Early in the COVID-19 pandemic, it was quickly established that the receptor binding domain (RBD) of the SARS-CoV-2 spike protein is a prime target for neutralizing antibodies. Now, scientists have found a second region of the spike protein that is targeted by dozens of antibodies, some of which exhibit ultrapotent neutralizing activity. Read more »
Conformational Dynamics in the Interaction of SARS-CoV-2 Papain-like Protease with Human Interferon-Stimulated Gene 15 Protein
The image depicts the complex formed between SARS-CoV-2 papain-like protease and human interferon-stimulated gene 15 protein. Small-angle scattering elucidated the structural details of this complex providing insight into its role in suppressing the innate immune response and also potential routes for development of therapeutics to combat COVID-19. Read more »
Guiding Target Selection for COVID-19 Antibody Therapeutics
Protein-structure studies helped demonstrate that the primary target of antibody-based COVID-19 immunity is the part of the virus’s spike protein that can most easily mutate. The work anticipated the rise of SARS-CoV-2 variants and guides the selection of antibody therapeutics that are likely to be more resistant to immune escape. Read more »
How X-Rays Could Make Reliable, Rapid COVID-19 Tests a Reality
A highly sensitive lateral flow assay—the same type of device used in home pregnancy tests—could be developed using pairs of rigid antibodies that bind to the SARS-CoV-2 nucleocapsid protein. SAXS data showed that a particular pair of monoclonal antibodies bound to the nucleocapsid protein very strongly and stably, in part due to the antibodies’ rigidity. Read more »